Five Steps to Improve Cardiac Safety of Attention Deficit Hyperactivity Disorder Treatment.
作者信息
Dopheide Julie A, Stutzman Danielle L
机构信息
University of Southern California Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences Titus Family Department of Clinical Pharmacy (JAD) and Keck School of Medicine Department of Psychiatry and the Behavioral Sciences (JAD), LA General Medical Center, Los Angeles, CA (JAD).
Pediatric Mental Health Institute (DLS), Children's Hospital Colorado, Aurora, CO.
出版信息
J Pediatr Pharmacol Ther. 2024 Dec;29(6):670-673. doi: 10.5863/1551-6776-29.6.670. Epub 2024 Dec 9.
Abstract
摘要
相似文献
1
Five Steps to Improve Cardiac Safety of Attention Deficit Hyperactivity Disorder Treatment.
J Pediatr Pharmacol Ther. 2024 Dec;29(6):670-673. doi: 10.5863/1551-6776-29.6.670. Epub 2024 Dec 9.
2
Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder.
Pediatrics. 2006 Sep;118(3):e704-10. doi: 10.1542/peds.2005-2947.
3
Comparative cardiovascular safety of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis.
Lancet Psychiatry. 2025 May;12(5):355-365. doi: 10.1016/S2215-0366(25)00062-8. Epub 2025 Apr 6.
4
Viloxazine extended-release capsules for the treatment of attention-deficit/ hyperactivity disorder in adult patients.
Expert Rev Neurother. 2023 Jul-Dec;23(11):945-953. doi: 10.1080/14737175.2023.2265068. Epub 2023 Oct 27.
5
Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
Clin Ther. 2007 Jun;29(6):1168-77. doi: 10.1016/j.clinthera.2007.06.017.
6
Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder.
Ann Pharmacother. 2006 Jun;40(6):1134-42. doi: 10.1345/aph.1G582. Epub 2006 May 30.
7
Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders.
Cochrane Database Syst Rev. 2018 Jun 26;6(6):CD007990. doi: 10.1002/14651858.CD007990.pub3.
8
Adverse Drug Reactions Related to Mood and Emotion in Pediatric Patients Treated for Attention Deficit/Hyperactivity Disorder: A Comparative Analysis of the US Food and Drug Administration Adverse Event Reporting System Database.
J Clin Psychopharmacol. 2019 Jul/Aug;39(4):386-392. doi: 10.1097/JCP.0000000000001058.
9
Assessment of centanafadine in adults with attention-deficit/hyperactivity disorder: A matching-adjusted indirect comparison vs lisdexamfetamine dimesylate, atomoxetine hydrochloride, and viloxazine extended-release.
J Manag Care Spec Pharm. 2024 Jun;30(6):528-540. doi: 10.18553/jmcp.2024.30.6.528.
10
Priapism associated with the use of stimulant medications and atomoxetine for attention-deficit/hyperactivity disorder in children.
Ann Pharmacother. 2014 Oct;48(10):1350-5. doi: 10.1177/1060028014541791. Epub 2014 Jun 30.
本文引用的文献
1
Practice Pearls for Stimulant Treatment of Attention-Deficit/Hyperactivity Disorder in Youth.
J Pediatr Pharmacol Ther. 2024 Jun;29(3):215-231. doi: 10.5863/1551-6776-29.3.215. Epub 2024 Jun 10.
2
Attention-Deficit/Hyperactivity Disorder Medications and Work Disability and Mental Health Outcomes.
JAMA Netw Open. 2024 Mar 4;7(3):e242859. doi: 10.1001/jamanetworkopen.2024.2859.
3
ADHD Pharmacotherapy and Mortality in Individuals With ADHD.
JAMA. 2024 Mar 12;331(10):850-860. doi: 10.1001/jama.2024.0851.
4
Association of Cannabis Use With Cardiovascular Outcomes Among US Adults.
J Am Heart Assoc. 2024 Mar 5;13(5):e030178. doi: 10.1161/JAHA.123.030178. Epub 2024 Feb 28.
5
Attention-Deficit/Hyperactivity Disorder Medications and Long-Term Risk of Cardiovascular Diseases.
JAMA Psychiatry. 2024 Feb 1;81(2):178-187. doi: 10.1001/jamapsychiatry.2023.4294.
6
Long-Term Cardiovascular Effects of Medications for Attention-Deficit/Hyperactivity Disorder-Balancing Benefits and Risks of Treatment.
JAMA Psychiatry. 2024 Feb 1;81(2):123-124. doi: 10.1001/jamapsychiatry.2023.4126.
7
Adverse Impact of Cannabis on Human Health.
Annu Rev Med. 2024 Jan 29;75:353-367. doi: 10.1146/annurev-med-052422-020627. Epub 2023 Aug 15.
8
Trends in Stimulant Prescription Fills Among Commercially Insured Children and Adults - United States, 2016-2021.
MMWR Morb Mortal Wkly Rep. 2023 Mar 31;72(13):327-332. doi: 10.15585/mmwr.mm7213a1.
9
Assessment and management of cardiovascular complications in eating disorders.
J Eat Disord. 2023 Jan 30;11(1):13. doi: 10.1186/s40337-022-00724-5.
10
Long-term methylphenidate exposure and 24-hours blood pressure and left ventricular mass in adolescents and young adults with attention deficit hyperactivity disorder.
Eur Neuropsychopharmacol. 2022 Nov;64:63-71. doi: 10.1016/j.euroneuro.2022.09.001. Epub 2022 Oct 7.
Zotero 插件